Inactive Instrument

News Kazia Therapeutics Australian S.E.

Equities

KZA

AU000000KZA9

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Kazia Therapeutics : Purchase Agreement - Form 6-K	Apr. 19	PU
Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP	Apr. 18	CI
Kazia Therapeutics : Corporate Presentation	Apr. 11	PU
Kazia Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Mar. 27	CI
Kazia Therapeutics : Half Yearly Report - 31 December 2023 - Form 6-K	Mar. 27	PU
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases	Mar. 21	PR
Kazia Therapeutics Limited Enters into an Exclusive Licensing Agreement Withsovargen Co., Ltd	Mar. 21	CI
Kazia Therapeutics : EVT801 Progress Update Presentation	Mar. 19	PU
Stocks Making Waves: Insights into Key Developments and Potential VTAK, TBIO, OCEA, ONMD, KZIA	Feb. 27	AQ
Kazia Therapeutics' Lead Drug Candidate Meets Goal of Early-Stage Study	Feb. 21	MT
Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint	Feb. 21	CI
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	Feb. 21	AQ
Certain Warrants of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.	Feb. 03	CI
Certain Ordinary Shares of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.	Feb. 03	CI
Certain American Depositary Shares of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.	Feb. 03	CI
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS	Jan. 18	PR
Kazia Therapeutics Limited Announces Appointment of Board Members	Jan. 18	CI
Kazia Therapeutics Limited Announces Resignation of Karen Krumeich as Chief Financial Officer	Jan. 12	CI
Kazia Therapeutics Limited Announces Executive Changes	Jan. 12	CI
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)	Dec. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kazia Therapeutics Australian S.E.

Equities

KZA

AU000000KZA9

Summary

Filters